Download Free Frontiers In Staphylococcus Aureus Book in PDF and EPUB Free Download. You can read online Frontiers In Staphylococcus Aureus and write the review.

Staphylococcus was first recognized as a human pathogen in 1880 and was named for its grape cluster-like appearance. In 1884, Staphylococcus aureus was identified and named for its vibrant golden color, which was later found to be the result of golden toxin production. Here, experts examine in-depth patterns of S. aureus colonization and exposures in humans, mammals, and birds that have led to the development of various clinical diseases. The mode of transmission of S. aureus and different methods for its detection in different samples are defined. Conventional antibiotic options to treat this aggressive, multifaceted, and readily adaptable pathogen are becoming limited. Alternative, novel chemotherapeutics to target S. aureus are discussed in the pages within, including herbal medicines, bee products, and modes of delivery.
Staphylococcus aureus S. aureus is a growing issue both within hospitals and community because of its virulence determinants and the continuing emergence of new strains resistant to antimicrobiotics. In this book, we present the state of the art of S. aureus virulence mechanisms and antibiotic-resistance profiles, providing an unprecedented and comprehensive collection of up-to-date research about the evolution, dissemination, and mechanisms of different staphylococcal antimicrobial resistance patterns alongside bacterial virulence determinants and their impact in the medical field. We include several review chapters to allow readers to better understand the mechanisms of methicillin resistance, glycopeptide resistance, and horizontal gene transfer and the effects of alterations in S. aureus membranes and cell walls on drug resistance. In addition, we include chapters dedicated to unveiling S. aureus pathogenicity with the most current research available on S. aureus exfoliative toxins, enterotoxins, surface proteins, biofilm, and defensive responses of S. aureus to antibiotic treatment.
This volume offers a comprehensive overview of basic and applied aspects of Staphylococcus aureus, which is one of the most important human pathogens. It includes sixteen chapters that address the microbiology and immunology of S. aureus, the pathology of its key manifestations, and the current standard of care. Further, it reviews cutting-edge advances in alternative therapeutic and prophylactic approaches to antibiotics. All chapters were written by respected experts in the field – presenting recent findings on a diverse range of aspects, they are nonetheless interlinked. As such, the book is a must-read for all researchers, clinicians and technicians engaged in basic or applied science work involving S. aureus.
Infections that occur in the wound created by an invasive surgical procedure are generally referred to as surgical site infections (SSIs). SSIs are one of the most important causes of healthcare-associated infections (HCAIs). A prevalence survey undertaken in 2006 suggested that approximately 8% of patients in hospital in the UK have an HCAI. SSIs accounted for 14% of these infections and nearly 5% of patients who had undergone a surgical procedure were found to have developed an SSI. However, prevalence studies tend to underestimate SSI because many of these infections occur after the patient has been discharged from hospital. SSIs are associated with considerable morbidity and it has been reported that over one-third of postoperative deaths are related, at least in part, to SSI. However, it is important to recognise that SSIs can range from a relatively trivial wound discharge with no other complications to a life-threatening condition. Other clinical outcomes of SSIs include poor scars that are cosmetically unacceptable, such as those that are spreading, hypertrophic or keloid, persistent pain and itching, restriction of movement, particularly when over joints, and a significant impact on emotional wellbeing. SSI can double the length of time a patient stays in hospital and thereby increase the costs of health care. Additional costs attributable to SSI of between £814 and £6626 have been reported depending on the type of surgery and the severity of the infection. The main additional costs are related to re-operation, extra nursing care and interventions, and drug treatment costs. The indirect costs, due to loss of productivity, patient dissatisfaction and litigation, and reduced quality of life, have been studied less extensively.
Staphylococcus spp. and Streptococcus spp. have not only got pathogenic isolates, but also non-pathogenic isolates. Staphylococcus spp. and Streptococcus spp. that are Gram positive cocci are the main pathogens in several infections. Virulence factors such as usual and unusual surface proteins encoded by resistance genes are the main causes of pathogenesis. Multidrug-resistant pathogens that are the main causes of morbidity and mortality worldwide have the ability to synthesize a number of destructive enzymes encoded by resistance genes such as ?-lactamases. Resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, Group A, and Group B Streptococcus have emerged throughout the world. To eliminate these resistant pathogens that cause untreatable, acute, and chronic infections, different new antimicrobials must be developed and used. The goal of this book is to provide the latest information about the above topics.
This book examines biofilms in nature. Organized into four parts, this book addresses biofilms in wastewater treatment, inhibition of biofilm formation, biofilms and infection, and ecology of biofilms. It is designed for clinicians, researchers, and industry professionals in the fields of microbiology, biotechnology, ecology, and medicine as well as graduate and postgraduate students.
Presents issues in food microbiology.
The use of microorganisms and their metabolites for the preservation of foods began in prehistory. Lactic acid bacteria are generally recognized as safe (GRAS) for this purpose. They produce organic acids, diacetyl, acetoin, hydrogen peroxide, reuterin, reutericyclin and bacteriocins, all of which inhibit foodborne pathogens and spoilage microorganisms. Bacteriocins and the strains that produce them are particularly effective as bio-preservatives in cheese, meat and vegetables. They hold the promise of ensuring the quality and safety of ready-to-eat, extended-shelf-life, fresh-tasting and minimally processed foods without chemical preservatives. This Research Topic provides an overview of bacterial cultures, bacteriocins and other metabolites that have shown promise for use as antimicrobial bio-preservatives in foods in general. Articles describing novel analytical technologies, strategies to reduce or eliminate pathogens in food systems or emerging technologies for the production or use of protective cultures or their bacteriocins are presented.
This comprehensive, authoritative treatise covers all aspects of mucosal vaccines including their development, mechanisms of action, molecular/cellular aspects, and practical applications. The contributing authors and editors of this one-of-a-kind book are very well known in their respective fields. Mucosal Vaccines is organized in a unique format in which basic, clinical, and practical aspects of the mucosal immune system for vaccine development are described and discussed. This project is endorsed by the Society for Mucosal Immunology. - Provides the latest views on mucosal vaccines - Applies basic principles to the development of new vaccines - Links basic, clinical, and practical aspects of mucosal vaccines to different infectious diseases - Unique and user-friendly organization
Surgical site infections are caused by bacteria that get in through incisions made during surgery. They threaten the lives of millions of patients each year and contribute to the spread of antibiotic resistance. In low- and middle-income countries, 11% of patients who undergo surgery are infected in the process. In Africa, up to 20% of women who have a caesarean section contract a wound infection, compromising their own health and their ability to care for their babies. But surgical site infections are not just a problem for poor countries. In the United States, they contribute to patients spending more than 400 000 extra days in hospital at a cost of an additional US $10 billion per year. No international evidence-based guidelines had previously been available before WHO launched its global guidelines on the prevention of surgical site infection on 3 November 2016, and there are inconsistencies in the interpretation of evidence and recommendations in existing national guidelines. These new WHO guidelines are valid for any country and suitable to local adaptations, and take account of the strength of available scientific evidence, the cost and resource implications, and patient values and preferences.